These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 38381679)

  • 1. CAR T Cells - A New Horizon for Autoimmunity?
    Isaacs JD
    N Engl J Med; 2024 Feb; 390(8):758-759. PubMed ID: 38381679
    [No Abstract]   [Full Text] [Related]  

  • 2. Off-the-shelf CAR T cells for refractory autoimmunity.
    Papatriantafyllou M
    Nat Rev Rheumatol; 2024 Sep; 20(9):527. PubMed ID: 39075289
    [No Abstract]   [Full Text] [Related]  

  • 3. Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy.
    Ghassemi S; Milone MC
    J Vis Exp; 2019 Dec; (154):. PubMed ID: 31904011
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epigenetic challenges on the horizon of chimeric antigen receptor-T.
    Benincasa G; Strozziero MG; Di Pastena MA; Criscuolo C; Cetani G; Trama U; Napoli C
    Cytotherapy; 2024 May; 26(5):411-412. PubMed ID: 38466261
    [No Abstract]   [Full Text] [Related]  

  • 5. Senolytic CAR T Cells in Solid Tumors and Age-Related Pathologies.
    Feucht J; Abou-El-Enein M
    Mol Ther; 2020 Oct; 28(10):2108-2110. PubMed ID: 32841587
    [No Abstract]   [Full Text] [Related]  

  • 6. The development of academic CAR T cells.
    Delgado J; Juan M; Calvo G; Urbano-Ispizua Á
    Lancet Haematol; 2024 Jul; 11(7):e484-e485. PubMed ID: 38937023
    [No Abstract]   [Full Text] [Related]  

  • 7. CAR T-cell expansion: harmful or helpful?
    Lionel AC; Neelapu SS
    Blood Adv; 2024 Jun; 8(12):3311-3313. PubMed ID: 38916899
    [No Abstract]   [Full Text] [Related]  

  • 8. Anti-CD166/4-1BB chimeric antigen receptor T cell therapy for the treatment of osteosarcoma.
    Wang Y; Yu W; Zhu J; Wang J; Xia K; Liang C; Tao H
    J Exp Clin Cancer Res; 2019 Apr; 38(1):168. PubMed ID: 30995926
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deciphering the response to BCMA CAR T cell therapy.
    Hassan H; Davila ML
    Nat Cancer; 2024 Sep; 5(9):1287-1288. PubMed ID: 39300321
    [No Abstract]   [Full Text] [Related]  

  • 10. CAR T cell therapy for multiple myeloma: where are we now and where are we headed?
    Ghosh A; Mailankody S; Giralt SA; Landgren CO; Smith EL; Brentjens RJ
    Leuk Lymphoma; 2018 Sep; 59(9):2056-2067. PubMed ID: 29105517
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo CAR T cells move into clinical trials.
    Mullard A
    Nat Rev Drug Discov; 2024 Oct; 23(10):727-730. PubMed ID: 39284972
    [No Abstract]   [Full Text] [Related]  

  • 12. Tracking non-relapse mortality after CAR T cell therapy.
    Blumenberg V; Maus MV
    Nat Med; 2024 Sep; 30(9):2413-2414. PubMed ID: 39215151
    [No Abstract]   [Full Text] [Related]  

  • 13. Efficiency and safety of autologous chimeric antigen receptor T-cells therapy used for patients with lymphoma: A systematic review and meta-analysis.
    Cao G; Lei L; Zhu X
    Medicine (Baltimore); 2019 Oct; 98(42):e17506. PubMed ID: 31626107
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Engineering CAR-T Cells for Next-Generation Cancer Therapy.
    Hong M; Clubb JD; Chen YY
    Cancer Cell; 2020 Oct; 38(4):473-488. PubMed ID: 32735779
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CAR T cells put the brakes on asthma.
    Lambrecht BN; Hammad H
    Nat Immunol; 2024 Jun; 25(6):935-937. PubMed ID: 38802513
    [No Abstract]   [Full Text] [Related]  

  • 16. Immune Cell Hacking: Challenges and Clinical Approaches to Create Smarter Generations of Chimeric Antigen Receptor T Cells.
    Elahi R; Khosh E; Tahmasebi S; Esmaeilzadeh A
    Front Immunol; 2018; 9():1717. PubMed ID: 30108584
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Primer on Chimeric Antigen Receptor T-cell Therapy: What Does It Mean for Pathologists?
    Cushman-Vokoun AM; Voelkerding KV; Fung MK; Nowak JA; Thorson JA; Duncan HL; Kalicanin T; Anderson MW; Yohe S
    Arch Pathol Lab Med; 2021 Jun; 145(6):704-716. PubMed ID: 33237994
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CAR-T Engineering: Optimizing Signal Transduction and Effector Mechanisms.
    Roselli E; Frieling JS; Thorner K; Ramello MC; Lynch CC; Abate-Daga D
    BioDrugs; 2019 Dec; 33(6):647-659. PubMed ID: 31552606
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multispecific Targeting with Synthetic Ankyrin Repeat Motif Chimeric Antigen Receptors.
    Balakrishnan A; Rajan A; Salter AI; Kosasih PL; Wu Q; Voutsinas J; Jensen MC; Plückthun A; Riddell SR
    Clin Cancer Res; 2019 Dec; 25(24):7506-7516. PubMed ID: 31548346
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CAR T Cells for Neuroblastoma.
    Yeku OO; Longo DL
    N Engl J Med; 2023 Apr; 388(14):1328-1331. PubMed ID: 37018497
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.